Blood coagulation and cancer: Thrombosis and survival, clinical relevance and impact: Thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 3-4, 2008, Pages 113-121

  Vestjens, J H M J ^a   Sassen, S ^b   Prins, M H ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VIECURI MEDICAL CENTER   (Netherlands)

^c Academic Medical Centre   (Netherlands)

Author keywords

Blood coagulation and cancer; Deep venous thrombosis; Occult cancer; Thrombosis and survival; Venous thrombotic event

Indexed keywords

ANTIVITAMIN K; COUMARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADD ON THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HUMAN; NEOPLASM; OCCULT CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; BLOOD; CANCER OF UNKNOWN PRIMARY SITE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETERIZATION; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; STATISTICS; THROMBOPHILIA;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; COHORT STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 61449093023     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000175149     Document Type: Review

References (81)

1. Bouillaud S: De l'oblitération des veines et de son influence sur la formation des hydropisies partielles: considération sur la hydropisies passive et général. Arch Gen Med 1823;1:188-204.
2. Trousseau A: Phlegmasia alba dolens;in Trousseau A (ed): Clinique médicinale de l'Hôtel-Dieu de Paris. Paris, J.-B. Baillière &Fils, 1865, pp 645-712.
3. Illtyd James T, Matheson N: Thrombophlebitis in cancer. Practitioner 1935;134:683-684.
4. Monreal M, Fernandez-Llamazares J, Peran-dreu J, Urrutia A, Sahuquillo JC, Contel E: Occult ca nc er i n pat ients w it h venous thromboembolism. Thromb Haemost 1997;78: 1316-1318.
5. Rance A, Emmerich J, Guedj C, Fiessinger J-N: Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 1997;350: 14 48-1449.
6. Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, Julian J: The occurrence of subsequent malignancy in patients with deep vein thrombosis: results from a historical cohort study. Thromb Haemost 1998;79: 19-22.
7. Prandoni P, Lensing AW, Buller HW, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133.
8. Hettiarachchi RJK, Lok J, Prins MH, Buller HR, Prandoni P: Undiagnosed malignancy in patients with deep vein thrombosis. Incidence, risk factors and diagnosis. Cancer 1998;83:180-185.
9. Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas EM, Martorell A: Occult ca ncer in pat ients w it h deep vein thrombosis. A systematic approach. Cancer 1991;67:541-545.
10. Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Mundo MR: Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest 1993;103:816-819.
11. Aderk a D, Brow n A , Zel i kov sk i A, P i n k has J: Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 1986;57:1846-1849.
12. Bastounis EA, Karayiannakis AJ, Makri GG, Alexiou D, Papalambros EL: The incidence of occult cancer in patients with deep vein thrombosis: a prospective study. J Intern Med 1996;239:153-156.
13. Oudega R, Moons KGM, Nieuwenhuis HK, Van Nierop FL, Hoes AW: Deep vein thrombosis in primary care: possible malignancy? Br J Gen Pract 2006;56:693-696.
14. Ronsdorf A, Perruchoud AP, Schoenenberger RA: Search for occult malignancy in patients with deep venous thrombosis. Swiss Med Wkly 2003;133:567-574.
15. Beckers MMJ, Schutgens REG, Prins MH, Biesma DH: Who is at risk for occult cancer after venous thromboembolism? J Thromb Haemost 2006;4:2731-2733.
16. Nordstrom M, Lindblad B, Anderson H, Bergqvist D, KjellstromT: Deep venous thrombosis and occult malignancy: an epidemiologica l study. BMJ 1994;308:891-894.
17. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L: Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Int Med 1996;125:785-793.
18. Goldberg RJ, Seneff M, Gore JM, Anderson FA Jr, Greene HL, Wheeler HB, Dalen JE: Occult malignant neoplasm in patients with deep vein thrombosis. Arch Intern Med 2005;165:1782-1787.
19. Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE: Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 1982;96:556-560.
20. Griffin MR, Stanson AW, Brown ML, Hauser MF, O'Fallon WM, Anderson HM, Kazmier FJ, Melton LJ 3rd: Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Intern Med 1987;14 7: 1907-1911.
21. Murchison JT, Wylie L, Stochton DL: Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohor t study. Br J Cancer 2004;91: 92-95.
22. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:116 9-1173.
23. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M: Venous thromboembolism and cancer. Lancet 1998;351:1077-1080.
24. White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T: Incidence of venous thromboembolism in the year before the diagnosis of cancer in 52,8693 adults. Arch Intern Med 2005;165:1782-1787.
25. White RH, Chew H, Wun T: Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? Thromb Res 2007;120(suppl 2):S29-S40.
26. Blom JW, Doggen CJM, Osanto S, Rosendaal FR: Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 2005;293:715-722.
27. Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H: Postoperative venous thromboembolism and brain tumors. I. Clinical profile. J Neurooncol 1992;14:119-125.
28. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR: Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994;69:329-332.
29. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 2005;6:401-410.
30. Rickles FR, Edwards RL: Activation of blood coagu lation in cancer: Trousseau's syndrome rev isited. Blood 1983;62:14-31.
31. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 2005;6: 401-410.
32. Von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L: Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77:456-461.
33. Sack GH, Levin J, Bell WR: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Medicine 1977;56:1-37.
34. Lieberman JS, Borrero J, Urdoncta E, Wright IS: Thrombophlebitis and cancer. JAMA 1961;177:542-545.
35. Rickles FR, Levine MN: Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998;28(suppl 3):43-49.
36. Sallah S, Wan JY, Nguyen NP: venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
37. Lee AY, Levine MN: Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107(23 suppl 1):I17-I21.
38. Haddad TC, Greeno EW: Chemotherapy-induced thrombosis. Thromb Res 2006;118: 555-568.
39. Seddighzadeh A, Shetty R, Goldhaber SZ: Venous thromboembolism in patients with active cancer. Thromb Haemost 2007;98: 656-661.
40. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon M, Melton J III: Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000;160:809-815.
41. Chew HK, Wun T, Harvey D, Zhou H, White R: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464.
42. Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH: Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006;24:1112-1118.
43. Monreal M, Alastrue A, Rull M, Mira X, Mu xar t J, Ro s el l R , Ab ad A : Upper e x t re mit y deep venous thrombosis in cancer patients with venous access devices- prophylaxis with a low-molecular-weight heparin (Fragmin). Thromb Haemost 1996;75:251-253.
44. Heit JA: Cancer and venous thromboembolism: scope of the problem. Cancer Control 2005;12(suppl 1):5-10.
45. Kakkar V V, Howe CT, Nicolaides AN, Renney JTG, Clarke MB: Deep vein thrombosis of the leg: is there a 'high-risk' group? Am J Surg 1970;120:527-531.
46. Pineo GD, Brain MC, Galkes AS, Hirsch J, Hatton MWC, Regoeczi E: Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 1974;230:262-270.
47. White RH, Zhou H, Romano PS: Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 20 03;90:446-455.
48. Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, Prins MH: Venous thromboembolism in patients treated with chemotherapy. An underestimated phenomenon. Arch Intern Med 2004;164:190-194.
49. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Da ly M, Wiea nd S , Ta n- Ch iu E , Ford L , Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
50. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerman DL, Fisher ER, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484.
51. Deitcher S, Gomes M: The risk of venous thromboembolism disease associated with adjuvant hormone therapy for breast carcinoma. A systematic review. Cancer 2004;101: 439-349.
52. Howell A: Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. La ncet 2005;365:60-62.
53. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villata S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH: The long-term clinical course of acute deep venous thrombosis. A nn Intern Med 1996;125:1-7.
54. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
55. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Buller HR: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
56. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA: Rates of initial and recurrent thromboembolic disease among pat ients w it h ma lignanc y versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.
57. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW: American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505.
58. Meyer G, Marjanov ic Z , Va lcke J, Lorcerie B, Gruel Y, et al: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. A randomized controlled study. Arch Intern Med 2002;162: 1729-1735.
59. Lee AY, Levine MN, Baker RI, Bowden Ch, Kakkar AK, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
60. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, et al: Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-1072.
61. Palareti G, Legnani C, Lee A, Manotti C, Hirsch J, D 'Angelo A , Pengo V, Moia M, Coccheri S: A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810.
62. Noble SIR, Finlay IG: Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Pall Med 2005;19:197-201.
63. Ambrus JL, Ambrus CM, Mink IB, Pickren JW: Causes of death in cancer patients. J Med 1975;6:61-64.
64. Shen VS, Pollak EW: Fatal pulmonary embolism in cancer patients: is heparin prophy-laxis justified? South Med J 1980;73:841-843.
65. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH: Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-490.
66. Komrokji RS, Uppal NP, Khorana AA, Lyman GH, Kaplan KL, et al: Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006;47: 1029-1033.
67. Manda la M, Reni M, Cascinu S , BarniS, Floriani I, et al: Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007;18: 1660-1665.
68. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
69. Tetsche MS, Norgaard M, Pedersen L, Lash TL, Sørensen HT: Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer 2006;6:189.
70. Chew HK, Wun T, Harvey DJ, Zhou H, White RH: Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-76.
71. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130: 800-809.
72. Siragusa S, Cosmi B, Piovella F, Hisch J, Ginsberg JS: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277.
73. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al: Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;89: 947-952.
74. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G: A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of ve nou s t hromboembol i sm. A rch Int e r n Me d 2000;160:181-188.
75. Lee AYY, Rickles FR, Julian JA, Gent M, Baker RL: Randomized comparison of low-molecular-weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
76. Kuderer NM, Khorana AA, Lyman GH, Francis CW: A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. Cancer 2007;110:1149-1160.
77. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA: The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5: 729-737.
78. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, et al: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2: 1266-1271.
79. Kakkar AK, Levine MN, Kadziola Z, Le-moine NR, Low V, et al: Low-molecular-weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
80. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, et al: Low-molecular-weight hepa-rin in patients with advanced cancer: a phase III clinical trial. Mayo Clin Proc 2006;81: 758-767.
81. Klerk CPW, Smorenburg SM, Otten H-M, Lensing AWA, Prins MH, et al: The effect of low-molecular-weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.